Categories: Press Release

Paul Gurbel, MD, Awarded Honorary Doctorate Degree from Nicolaus Copernicus University

FALLS CHURCH, VA – February 19, 2016 – World-renowned interventional cardiologist at the Inova Heart and Vascular Institute (IHVI), Paul A. Gurbel, MD, today was awarded an honorary doctorate degree from Nicolaus Copernicus University in Poland.

The “Doctor Honoris Causa,” the University’s highest distinction, was presented to Dr. Gurbel by Rector Andrzej Tretyn and Dean Andrzej Kowalczyk in recognition of his contributions to cardiovascular clinical research, his leadership in the discovery and development of breakthrough clinical pharmacology and medical devices, and his service to the international scientific community.

As Director of Interventional Cardiology and Cardiovascular Medicine Research at IHVI, Dr. Gurbel leads research and clinical trials focused on the effects and development of antiplatelet agents. His laboratory pioneered the concept of antiplatelet response variability and his research led to the development of new P2Y12 inhibitors. He holds patents in the fields of interventional cardiology and antithrombotic therapy.

“Dr. Gurbel’s research is fundamental to our understanding of the risk of bleeding and clotting in cardiovascular patients,” said Christopher O’Connor, MD, CEO and Executive Director, IHVI. “It has changed the way we treat patients today.”

Dr. Gurbel recently assisted in the implantation of a state-of-the-art heart monitoring device called CardioMEMS, making Inova one of the first hospitals in the United States to use this device to treat a patient with advanced heart failure. He continues to make significant advancements in interventional cardiology, treatment of complex coronary artery disease, and personalized care.

“The Doctor Honoris Causa is a great honor,” said Dr. Gurbel. “It is an acknowledgement of the dedication of our team and the important advances we have made in the areas of platelet physiology, antithrombotic drug development and personalization of antiplatelet therapy. I am indebted to my research team who has worked tirelessly over the last 15 years to make this award possible. This award is as much theirs as it is mine, and I look forward to continuing ground-breaking research and care at Inova.”

Dr. Gurbel earned his medical degree at the University of Maryland School of Medicine and completed an internship and residency in Internal Medicine at Duke University Medical School.

Media Contact: Tracy Connell, tracy.connell@inova.org

InovaNewsroom

Share
Published by
InovaNewsroom

Recent Posts

Giving the gift of life: Demystifying the process of becoming a living kidney donor

Heather Perez Saiz, MA, LCSW, CCTSW, is the Independent Living Donor Advocate at Inova Fairfax…

22 hours ago

Inova Schar Heart and Vascular receives $1.4 million pediatric heart transplant research grant

Palak Shah, MD, MS Fairfax, VA — A research team at Inova Schar Heart and…

2 days ago

7 ways to lower blood pressure naturally

Jason Bonomo, MD, PhD, is a cardiologist at Inova Schar Heart and Vascular. Dr. Bonomo…

4 days ago

Inova plays a key role in trial of innovative treatment for tricuspid valve regurgitation that is now approved by the FDA

Update as of April 24, 2024: Inova’s structural heart team has now completed the first…

1 week ago

Inova receives $20 million gift from the Peterson Family to support critical needs

The Peterson Family Fairfax, VA, April 16, 2024 –  Inova today announced a transformational gift…

2 weeks ago

Mindful, intuitive eating for health: ditching the diet and feeding the soul

Lauren Trahan, MS, RD is a Registered Dietitian. She serves patients in Inova Cardiac and…

2 weeks ago